Cibisatamab is under clinical development by F. Hoffmann-La Roche and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cibisatamab’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cibisatamab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cibisatamab overview

Cibisatamab (RG-7802) is under development for the treatment of advanced metastatic CEA-positive solid tumors including metastatic colorectal cancer, squamous non-small cell lung cancer (first and third line therapy), breast cancer, pancreatic cancer, gastric cancer including gastroesophageal junction cancer. The drug candidate is administered through intravenous route. This antibody acts as a bi-specific T-cell engager. The drug candidate acts by targeting carcinoembryonic antigen (CEA, CEACAM5, and CD66e) antigen on tumor cells and CD3 on T cells. It is a new molecular entity (NME).

F. Hoffmann-La Roche overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

Quick View Cibisatamab LOA Data

Report Segments
  • Innovator
Drug Name
  • Cibisatamab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.